The Efficacy of Tenofivir to Prevent Perinatal Transmission in Chronic Hepatitis BMothers. AClinical Perspective
Ghassan Mubarak, Richard Ferstenberg – 2 August 2018
Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases
Keith D. Lindor, Christopher L. Bowlus, James Boyer, Cynthia Levy, Marlyn Mayo – 2 August 2018
Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases
Keith D. Lindor, Christopher L. Bowlus, James Boyer, Cynthia Levy, Marlyn Mayo – 2 August 2018
A New Concept: Pre‐HCC Disease
Yao Yang, Yuemin Feng, Xinya Zhao, Le Wang, Xiaoyu Xie, Jie Li, Mindie H. Nguyen, Qiang Zhu – 2 August 2018
Reply
Norah A. Terrault, Robert S. Brown, Anna SF Lok, John B Wong, Natalie H Bzowej, Kyong‐Mi Chang, Jessica P Hwang, Maureen M Jonas, Brian J McMahon – 2 August 2018
Vascular Immunotargeting: Take the Highway to the First Exit
Vladimir R. Muzykantov, Jacob S. Brenner – 2 August 2018
Lactate Improves Prediction of Short‐Term Mortality in Critically Ill Patients With Cirrhosis: A Multinational Study
Andreas Drolz, Thomas Horvatits, Karoline Rutter, Felix Landahl, Kevin Roedl, Philippe Meersseman, Alexander Wilmer, Johannes Kluwe, Ansgar W. Lohse, Stefan Kluge, Michael Trauner, Valentin Fuhrmann – 2 August 2018 – Lactate levels and lactate clearance are known predictors of outcome in critically ill patients in the intensive care unit (ICU). The prognostic value of lactate is not well established in liver cirrhosis and acute‐on‐chronic liver failure (ACLF). The aim of this study was to assess the prognostic value of lactate levels and clearance in critically ill patients with cirrhosis.
Liver Transplant Listing in Pediatric Acute Liver Failure: Practices and Participant Characteristics
James E. Squires, David A. Rudnick, Regina M. Hardison, Simon Horslen, Vicky L. Ng, Estella M. Alonso, Steven H. Belle, Robert H. Squires – 2 August 2018 – Liver transplant (LT) decisions in pediatric acute liver failure (PALF) are complex. Three phases of the PALF registry, containing data on 1,144 participants over 15 years, were interrogated to characterize clinical features associated with listing status. A decrease in the cumulative incidence of listing (P < 0.005) and receiving (P < 0.05) LT occurred without an increase in the cumulative incidence of death (P = 0.67).
A Case of Immune‐Mediated Liver Injury Induced by Olaparib
Manuel Tufoni, Carmen Serena Ricci, Giacomo Zaccherini – 2 August 2018
Short‐Duration AL‐335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis
Edward J. Gane, Catherine A. Stedman, Christian Schwabe, Leen Vijgen, Sushmita Chanda, Thomas N. Kakuda, John Fry, Lawrence M. Blatt, Matthew W. McClure – 2 August 2018 – This open‐label, phase IIa study assessed the safety, pharmacokinetics, and efficacy of direct‐acting antiviral agent (DAA) regimens in patients with chronic hepatitis C virus (HCV) infection. Multiple 6‐12‐week oral regimens of 400‐800 mg once daily (QD) AL‐335 + 50 mg QD/every other day odalasvir ± 75‐150 mg QD simeprevir were evaluated in treatment‐naïve, HCV genotype (GT)1/3‐infected patients without cirrhosis.